Publication & Citation Trends
Publications
0 total
Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma
Cited by 0
Semantic Scholar
Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial.
Cited by 9
Semantic Scholar
A Phase 2 Study Measuring MRD Negativity after Talquetamab and Teclistamab Consolidation in Sequence As Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients (TALTEC)
Cited by 0
Semantic Scholar
Selinexor with alternating bortezomib or lenalidomide plus dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients (SABLe), report of primary endpoint, nordic myeloma study group 29/21
Cited by 0
Semantic Scholar
Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study
Cited by 0
Semantic Scholar
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease OA
Cited by 9
Semantic Scholar
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group OA
Cited by 4
Semantic Scholar
Research Topics
Multiple Myeloma Research and Treatments
(1)
Cancer Treatment and Pharmacology
(1)
Protein Degradation and Inhibitors
(1)
Affiliations
Stavanger University Hospital